Agent BZ (3-quinuclidinyl benzilate) is a centrally acting synthetic anticholinergic agent, considered as a potential military incapacitating chemical warfare agent. Despite its significance as a model compound in pharmacological research and its potential misuse in chemical attacks, few modern analytical methods for BZ determination in biological samples have been published. The goal of the present work is to develop and validate a sensitive and rapid LC-MS/MS method for the determination of agent BZ in rat plasma. The sample preparation was based on solid-phase extraction on C-18 cartridges. The reversed-phase HPLC coupled with the mass spectrometer with electrospray ionization in the positive ion-selective reaction monitoring mode was employed in the BZ analysis. Atropine was used as an internal standard. The presented method is selective, accurate, precise, and linear (r2 = 0.9947) in a concentration range from 0.5 ng/mL to 1 000 ng/mL and sensitive enough (limit of detection 0.2 ng/mL; limit of quantification 0.5 ng/mL) to determine the BZ plasma levels in rats exposed to 2 mg/kg and 10 mg/kg of BZ. The highest level of BZ in plasma was observed 5 minutes after intramuscular administration (154.6 ± 22.3 ng/mL in rats exposed to 2 mg/kg of BZ and 1024 ± 269 ng/mL in rats exposed to 10 mg/kg). After 48 h, no BZ was observed at detectable levels. This new method allows the detection and quantification of BZ in biological samples after exposure of an observed organism and it will be further optimized for other tissues to observe the distribution of BZ in organs.

Department of Pharmaceutical Chemistry and Pharmaceutical Analysis Charles University Faculty of Pharmacy in Hradec Kralove Czech Republic

Department of Toxicology and Military Pharmacy University of Defense Faculty of Military Health Sciences Czech Republic

Zobrazit více v PubMed

Liu J, Uchea C, Wright L, Pope C. Chapter 34 - Chemical warfare agents and the nervous system. In: Gupta RC, editor. Handbook of Toxicology of Chemical Warfare Agents. 2nd ed. Boston: Academic Press; 2015:463-475. https://doi.org/10.1016/B978-0-12-800159-2.00034-8

Science and Technology. OPCW. https://www.opcw.org/resources/science-and-technology. Accessed 22 October 2019.

Syria chemical “attack”: What we know. https://www.bbc.com/news/world-middle-east-39500947. Published 26 April 2017. Accessed 15 April 2019.

Chauhan S, Chauhan S, D'Cruz R, et al. Chemical warfare agents. Environ Toxicol Pharmacol. 2008;26(2):113-122. https://doi.org/10.1016/j.etap.2008.03.003

3-Quinuclidinyl Benzilate Poisoning: Background, Pathophysiology, Epidemiology. February 2019. https://emedicine.medscape.com/article/833155-overview. Accessed 15 April 2019.

McRee RC, Boulay SF, Sood VK, et al. Autoradiographic evidence that QNB displays in vivo selectivity for the m2 subtype. Neuroimage. 1995;2(1):55-62. https://doi.org/10.1006/nimg.1995.1008

Nobrega JN, Raymond RJ, Pollock BG. An improved, high-efficiency assay for assessing serum anticholinergic activity using cultured cells stably expressing M1 receptors. J Pharmacol Toxicol Methods. 2017;86:28-33. https://doi.org/10.1016/j.vascn.2017.03.001

Schneider PG, López Ordieres MG, Rodríguez de Lores Arnaiz G. Neurotensin modulates central muscarinic receptors, an effect which does not involve the high-affinity neurotensin receptor (NTS1). Regul Pept. 2010;163(1-3):37-42. https://doi.org/10.1016/j.regpep.2010.04.002

Ouchi K, Yamagishi-Wang H, Sawaki K, Watanabe M, Kawano T, Kawaguchi M. Modulation of benzodiazepine receptor, adrenoceptor and muscarinic receptor by diazepam in rat parotid gland. Eur J Pharmacol. 2011;657(1-3):20-25. https://doi.org/10.1016/j.ejphar.2011.01.029

Schneider PG, Rodríguez de Lores Arnaiz G. Ketamine prevents seizures and reverses changes in muscarinic receptor induced by bicuculline in rats. Neurochem Int. 2013;62(3):258-264. https://doi.org/10.1016/j.neuint.2012.12.013

Sterin-Borda L, Orman B, De Couto PA, Borda E. Inflammation triggers constitutive activity and agonist-induced negative responses at M(3) muscarinic receptor in dental pulp. J Endod. 2011;37(2):185-190. https://doi.org/10.1016/j.joen.2010.11.021

Kobayashi H, Suzuki T, Sakamoto M, et al. Brain regional acetylcholinesterase activity and muscarinic acetylcholine receptors in rats after repeated administration of cholinesterase inhibitors and its withdrawal. Toxicol Appl Pharmacol. 2007;219(2-3):151-161. https://doi.org/10.1016/j.taap.2006.11.006

Evangelou A, Zikos C, Benaki D, et al. In vitro binding and in vivo biodistribution studies of the neuroprotective peptide humanin using [125I]humanin derivatives. Peptides. 2009;30(12):2409-2417. https://doi.org/10.1016/j.peptides.2009.07.028

Misik J, Kassa J. A comparison of cholinesterase inhibitors in the treatment of quinuclidinyl benzilate-induced behavioural deficit in rats performing the multiple T-maze. J Appl Biomed. 2014;12(4):211-217. https://doi.org/10.1016/j.jab.2014.01.006

Misik J, Korabecny J, Nepovimova E, Kracmarova A, Kassa J. Effects of novel tacrine-related cholinesterase inhibitors in the reversal of 3-quinuclidinyl benzilate-induced cognitive deficit in rats - is there a potential for Alzheimer's disease treatment? Neurosci Lett. 2016;612:261-268. https://doi.org/10.1016/j.neulet.2015.12.021

Misik J, Vanek J, Musilek K, Kassa J. Cholinergic antagonist 3-quinuclidinyl benzilate - impact on learning and memory in Wistar rats. Behav Brain Res. 2014;266:193-200. https://doi.org/10.1016/j.bbr.2014.03.001

guideline-bioanalytical-method-validation_en.pdf. https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-bioanalytical-method-validation_en.pdf. Accessed 15 April 2019.

PubChem. 3-Quinuclidinyl benzilate. https://pubchem.ncbi.nlm.nih.gov/compound/23056. Accessed 22 October 2019.

Halámek E, Kobliha Z, Pitschmann V. Quinuclidin-3-yl diphenylhydroxyacetate, BZ compound. In: Analysis of Chemical Warfare Agents. Vol.2009 Vyškov: Univerzita obrany:131-139.

Hackley BE, Cochrane CC, Hackley EB Jr. Some chemical reactions of BZ. May 1964. https://i2.cdn.turner.com/cnn/2012/images/02/15/bz.study.pdf Accessed 15 April 2019

Angelis K, Bardoděj Z, Samcová E, Šrám RJ. Studium časového průběhu účinku a hladiny látky BZ a benzilátů po intraperitoneální aplikaci u krys: Závěrečná zpráva dílčí výzkumné etapy úkolu Z-12-3/7.Praha: Institut hygieny a epidemiologie. 1975.

Abbara C, Bardot I, Cailleux A, et al. High-performance liquid chromatography coupled with electrospray tandem mass spectrometry (LC/MS/MS) method for the simultaneous determination of diazepam, atropine and pralidoxime in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci. 2008;874(1-2):42-50. https://doi.org/10.1016/j.jchromb.2008.08.027

Marques GLM, Siqueira AA, Minassa VS, Peres MD, Pelição FS, Sampaio KN. Method validation for simultaneous determination of atropine, pralidoxime and 12 organophosphorus compounds in blood samples by means of high-performance liquid chromatography coupled with tandem mass spectrometry (LC-MS/MS). J Chromatogr B Analyt Technol Biomed Life Sci. 2018;1097-1098:44-53. https://doi.org/10.1016/j.jchromb.2018.09.006

Boermans PA, Go HS, Wessels AM, Uges DR. Quantification by HPLC-MS/MS of atropine in human serum and clinical presentation of six mild-to-moderate intoxicated atropine-adulterated-cocaine users. Ther Drug Monit. 2006;28(3):295-298. https://doi.org/10.1097/01.ftd.0000198537.41835.71

John H, Binder T, Höchstetter H, Thiermann H. LC-ESI MS/MS quantification of atropine and six other antimuscarinic tropane alkaloids in plasma. Anal Bioanal Chem. 2010;396(2):751-763. https://doi.org/10.1007/s00216-009-3209-7

Büch U, Isenberg E, Büch HP. HPLC assay for atropine in serum and protein solutions after in vitro addition of the tropane alkaloid. Methods Find Exp Clin Pharmacol. 1994;16(5):361-365.